Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anna Walley

Nurse Practitioner, Family Jackson, MS Nurse Practitioner

NPI 1528373586 CMS profile 205725

501 Marshall Street, Suite 200, Jackson, MS 39202

Open in the dashboard

General payments

$17,298

669 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Walley of Jackson, MS is reported in the CMS Open Payments database as having received $17,298 across 669 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,067 149
2024 General $4,529 137
2023 General $4,956 129
2022 General $2,372 126
2021 General $2,373 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Walley
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Anna Walley were reported at $3,067. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Anna Walley Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,373 $124 $35–$379 $132
2022 $2,372 $141 $44–$430 $149
2023 $4,956 $154 $49–$476 $160
2024 $4,529 $165 $51–$504 $164
2025 $3,067 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Inspire Medical Systems, Inc. $4,695 39 payments
  2. GlaxoSmithKline, LLC. $3,174 185 payments
  3. AstraZeneca Pharmaceuticals LP $1,434 55 payments
  4. Jazz Pharmaceuticals Inc. $980 39 payments
  5. Mallinckrodt Hospital Products Inc. $912 46 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $838 51 payments
  7. Genzyme Corporation $665 27 payments
  8. Actelion Pharmaceuticals US, Inc. $627 24 payments
  9. ANI Pharmaceuticals, Inc. $475 5 payments
  10. Axsome Therapeutics, Inc. $471 18 payments
  11. Other $3,028 180 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,055 649 payments
  2. Travel and Lodging $3,042 15 payments
  3. Education $202 5 payments
Products named General payments · program years 2021–2025
  1. INSPIRE $4,695 39 payments
  2. TRELEGY ELLIPTA $1,816 121 payments
  3. NUCALA $1,203 61 payments
  4. ACTHAR $912 46 payments
  5. XYWAV $884 34 payments
  6. OFEV $780 48 payments
  7. BREZTRI $754 21 payments
  8. DUPIXENT $665 27 payments
  9. FASENRA $647 19 payments
  10. UPTRAVI $627 24 payments
  11. Other $6,446 307 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

3,733

Median for Nurse Practitioner: 389

Drug cost

$1,381,240

Median for Nurse Practitioner: $21,885

Branded share of claims

47.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Uptravi Selexipag Brand 22 $483,174
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 532 $426,680
Breo Ellipta Fluticasone/Vilanterol Brand 119 $60,524
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 72 $53,792
Eliquis Apixaban Brand 66 $52,632
Xarelto Rivaroxaban Brand 46 $49,258
Symbicort Budesonide/Formoterol Fumarate Brand 146 $46,455
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 74 $35,805
Spiriva Handihaler Tiotropium Bromide Brand 47 $27,168
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 36 $26,817

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$149,271

Of which drugs: $3,709

Medicare patients

1,003

Average age 74

Services billed

4,509

580 women, 423 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
COPD 42%
Diabetes 37%
Ischemic heart disease 37%
Atrial fibrillation 25%
Chronic kidney disease 23%
Depression 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 23 23 $2,705
Influenza vaccine, trivalent derived from cell cultures 90661 Office 19 19 $686
Injection, ceftriaxone sodium, per 250 mg J0696 Office 44 208 $71
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 15 202 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $439
$439 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $335
$335 532 —
DUPIXENT
  • GENZYME CORPORATION $203
  • Regeneron Healthcare Solutions, Inc. $62
$265 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $251
$251 — —
NUCALA
  • GlaxoSmithKline, LLC. $220
$220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

669 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record